Stock Analysis of BiondVax Pharmaceuticals Ltd. (BVXV) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BVXV
Close 1.36
Change 0.050 / 3.82 %
Volume 22668.00
Vol Change 19750.00 / 676.83 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of BiondVax Pharmaceuticals Ltd.
PE (TTM)

140.98

Very Poor
Price / Book

1099.29

Very Poor
Price / Sales

348.44

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

4966.62 K

Enterprise Value

11355.62 K

ROA (TTM)

10.63

Good
ROE (TTM)

779.74

Excellent
Net Margin (TTM)

247.15

Excellent
Revenue

100.00 %

0
Net Profit

85.50 %

-5796.00 K
Debt to Equity

-11.63

Very Poor
Altman Z Score

-6.70

Very Poor
Quick Ratio

0

Poor
Cash Ratio

6.02

Excellent


Highs/Lows of BiondVax Pharmaceuticals Ltd.
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.34 1.49 % 1.54 % 1.371.301-Sep-2301-Sep-23
Two Week1.3 4.62 % 3.42 % 1.391.2928-Aug-2325-Aug-23
One Month1.38 1.45 % 5.60 % 1.391.2528-Aug-2322-Aug-23
Three Month1.4316 5.00 % 5.95 % 1.871.2512-Jul-2322-Aug-23
Six Months2.27 40.09 % 17.48 % 2.441.2517-Apr-2322-Aug-23
One year10.26 86.74 % 27.52 % 99.01.2523-Nov-2222-Aug-23
Two year24.6 94.47 % 29.70 % 99.01.2523-Nov-2222-Aug-23
Five year56.2 97.58 % 85.46 % 99.01.2523-Nov-2222-Aug-23


Technical View of BiondVax Pharmaceuticals Ltd.
RSI

52.52

Neutral
MACD

-0.0093

Bullish
ADX

21.24

Neutral
Super Trend

1.43

Mild Bearish
Williams %R

-21.43

Neutral
CCI

86.60

Neutral


EMA 5

1.34

Bullish
EMA 15

1.33

Neutral
EMA 50

1.40

Mild Bearish
EMA 100

1.86

Mild Bearish
SMA 100

1.55

Mild Bearish
SMA 200

3.96

Mild Bearish
SMA 5 / 20

1.33 / 1.32

Mild Bearish
SMA 15 / 50

1.33 / 1.37

Mild Bearish
SMA 50 / 200

1.37 / 3.96

Mild Bearish




Charts of BiondVax Pharmaceuticals Ltd.


Returns of BiondVax Pharmaceuticals Ltd. with Peers
Period / StockBVXVMYMDPRTGDRUG
1 Week1.49%-6.00%1.51%3.76%
1 Mth-1.45%4.44%15.78%-3.51%
3 Mth-5.00%-25.40%-51.03%-43.59%
6mth-40.09%-72.99%-82.64%-13.13%
1 Year-86.74%-96.14%-92.02%-60.51%
2 Year-94.47%-96.69%-96.02%-78.43%
5 Years-97.58%-99.78%--
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of BiondVax Pharmaceuticals Ltd. with Peers
Ratio / StockBVXVMYMDPRTGDRUG
PE140.98-0.651-0.0362-0.495
P/B1099.290.5770.1010.413
ROA10.63-38.36-211.47-76.79
ROE779.74-47.20-277.43-83.45
Debt To Equity-11.63-0.54500.0111
Revenue0
100.00 % 		0
% 		0
% 		0
%
Net Income-5796.00 K
85.50 % 		-5381.91 K
64.39 % 		-104611.00 K
520.10 % 		-7372.23 K
50.74 %


Technicals of BiondVax Pharmaceuticals Ltd. with Peers
Technical / StockBVXVMYMDPRTGDRUG-
ADX21.2422.1116.6824.30
CMF-0.078-0.0264-0.366-0.138
MFI67.9163.3576.3440.29
RSI52.5242.0540.3447.72
MACD Abv SignalTrueFalseTrueTrue
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : BiondVax Pharmaceuticals Ltd ADR

Address : Jerusalem BioPark Building, Jerusalem, Israel
Tel : 972 8 930 2529
URL : https://www.biondvax.com
Code : BVXV, ISIN : US09073Q1058, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 12_May_2015
Employee Count : 33

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.


Note : All Data Generated at the End of Trading Hours (EOD Data)